<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KITABIS PAK- tobramycin solution </strong><br>Pari Respiratory Equipment<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use KITABIS™ PAK safely and effectively. See full prescribing information for KITABIS PAK. <br>KITABIS PAK (tobramycin inhalation solution), for oral inhalation use<br>Initial U.S. Approval: 1975
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">KITABIS PAK contains tobramycin, an aminoglycoside antibacterial drug indicated for the management of <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> <span class="Italics">in adults and pediatric</span> patients <span class="Italics">6 years of age and older</span> with <span class="Italics">Pseudomonas aeruginosa</span> (<a href="#s1">1</a>).
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>KITABIS PAK is a co-packaging of tobramycin inhalation solution with a PARI LC PLUS® Reusable Nebulizer (<a href="#s3">2.1</a>).
</li>
<li>Administer tobramycin inhalation solution as one single–use ampule (300 mg/5 mL) twice a day by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug (<a href="#s3">2.1</a>).
</li>
<li>Dosage is not adjusted by weight (<a href="#s3">2.1</a>).
</li>
<li>Take doses as close to 12 hours apart as possible; but not less than 6 hours apart (<a href="#s3">2.1</a>)
</li>
<li>Administer each 300 mg dose using the PARI LC PLUS Reusable Nebulizer and DeVilbiss® PulmoAide® compressor (<a href="#s4">2.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Inhalation solution: 300 mg in a single-use 5 mL ampule (<a href="#s5">3</a>)
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any aminoglycoside (<a href="#s6">4</a>).
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>:</span>  Can occur with inhalation of tobramycin inhalation solution. Treat as medically appropriate, if it occurs (<a href="#s8">5.1</a>).
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span>:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> and <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> have been reported in patients receiving tobramycin inhalation solution. .  If noted, manage as medically appropriate, including potentially discontinuing tobramycin inhalation solution (<a href="#s9">5.2</a>).
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>:</span> Has been associated with aminoglycosides as a class. If <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> develops, manage the patient as medically appropriate, including potentially discontinuing tobramycin inhalation solution(<a href="#s10">5.3</a>).
</li>
<li>
<span class="Italics">Neuromuscular Disorders:</span> Aminoglycosides may aggravate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> because of a potential curare-like effect on neuromuscular function. If <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> occurs, it may be reversed by the administration of calcium salts but mechanical assistance may be necessary. (<a href="#s11">5.4</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (&gt; 5%) in patients treated with tobramycin inhalation solution were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, and increased <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> (<a href="#s15">6.1</a>).
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact PARI at 1-844 KITABIS (1-844-548-2247) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Concurrent and/or sequential use with other drugs with neurotoxic, nephrotoxic or ototoxic potential should be avoided (<a href="#s18">7.1</a>).
</li>
<li>Concomitant administration with ethacrynic acid, furosemide, urea, or intravenous mannitol is not recommended due to possible enhancement of aminoglycoside toxicity (<a href="#s19">7.2</a>).
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 12/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Administration of Tobramycin Inhalation Solution
</a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS AND STRENGTH
</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Neuromuscular Disorders
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Embryo-Fetal Toxicity
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Concomitant Use of Systemic Aminoglycosides
</a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs with Neurotoxic, Nephrotoxic or Ototoxic Potential
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Diuretics
</a></h2>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">10. OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12. CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology
</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14. CLINICAL STUDIES
</a></h1>
<h1><a href="#section-14" class="toc">15. REFERENCES
</a></h1>
<h1><a href="#section-15" class="toc">16. HOW SUPPLIED / STORAGE AND HANDLING
</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied
</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage
</a></h2>
<h1><a href="#section-16" class="toc">17. PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE
</h1>
<p class="First">KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> in adults and pediatric patients 6 years of age and older with <span class="Italics">P. aeruginosa.</span>  Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV<span class="Sub">1</span> &lt;25% or &gt;75% predicted, or patients colonized with <span class="Italics">Burkholderia cepacia [see Clinical Studies (<a href="#s36">14</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information
</h2>
<ul class="Disc">
<li>KITABIS PAK is a co-packaging of tobramycin inhalation solution ampules with a PARI LC PLUS Reusable Nebulizer. Administer as follows: One single-use ampule (300 mg /5 mL) of tobramycin inhalation solution twice a day by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug.
</li>
<li>The 300 mg/5mL dose of tobramycin inhalation solution is the same for all patients regardless of age or weight.
</li>
<li>The doses should be taken as close to 12 hours apart as possible; they should not be taken less than 6 hours apart.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Administration of Tobramycin Inhalation Solution
</h2>
<p class="First">Each dose of tobramycin inhalation solution is administered by oral inhalation using only the co-packaged PARI LC PLUS Reusable Nebulizer (Model No. 022B81-T) included in the KITABIS PAK, along with a DeVilbiss Pulmo-Aide air compressor (Model No. 5650D).</p>
<p>Tobramycin inhalation solution is <span class="Italics Underline">not</span> for subcutaneous, intravenous or intrathecal administration.</p>
<p>Prior to administration, read the <span class="Italics">Patient Information</span>/<span class="Italics">Instructions for Use</span> for KITABIS PAK for detailed information on how to use KITABIS PAK and follow the manufacturer's instructions for use and care of the DeVilbiss Pulmo-Aide air compressor.</p>
<p>The entire tobramycin inhalation solution treatment should take approximately 15 minutes to complete. Continue treatment until all the tobramycin inhalation solution has been delivered, and there is no longer any mist being produced.</p>
<p>Tobramycin inhalation solution should not be diluted or mixed with other drugs including dornase alfa (Pulmozyme®) in the nebulizer. Instruct patients on multiple therapies to take their medications prior to inhaling the tobramycin inhalation solution, or as directed by their physician.</p>
<p>Tobramycin inhalation solution should not be used if it is cloudy, if there are particles in the solution, or if it has been stored at room temperature for more than 28 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s5"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS AND STRENGTH
</h1>
<p class="First">Inhalation solution: 300 mg/5mL in a single-use ampule
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s6"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS
</h1>
<p class="First">Tobramycin inhalation solution is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any aminoglycoside.
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> can occur with inhalation of tobramycin inhalation solution. In clinical studies with tobramycin inhalation solution, changes in FEV<span class="Sub">1</span> measured after the inhaled dose were similar in tobramycin inhalation solution and placebo groups. <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> that occurs during the use of tobramycin inhalation solution should be treated as medically appropriate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span>
</h2>
<p class="First">Transient <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> occurred in eight tobramycin inhalation solution treated patients versus no placebo patients in the clinical studies. <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> may be a sentinel symptom of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>, and therefore the onset of this symptom warrants further clinical investigation. In postmarketing experience, patients receiving tobramycin inhalation solution have reported <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>. <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span>, manifested as both auditory and vestibular toxicity, has been reported with parenteral aminoglycosides. Vestibular toxicity may be manifested by <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Patients with known or suspected auditory or vestibular dysfunction should be closely monitored when taking tobramycin inhalation solution. Monitoring might include obtaining audiometric evaluations and serum tobramycin levels. If <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> is noted, the patient should be managed as medically appropriate, including potentially discontinuing tobramycin inhalation solution <span class="Italics">[see Adverse Reactions (<a href="#s16">6.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> was not seen during clinical studies with tobramycin inhalation solution but has been associated with aminoglycosides as a class. Patients with known or suspected renal dysfunction or taking concomitant nephrotoxic drugs along with tobramycin inhalation solution should have serum concentrations of tobramycin and laboratory measurements of renal function obtained at the discretion of the treating physician. If <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> develops, the patient should be managed as medically appropriate, including potentially discontinuing tobramycin inhalation solution.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Neuromuscular Disorders
</h2>
<p class="First">Aminoglycosides, including tobramycin, may aggravate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> because of a potential curare-like effect on neuromuscular function.  <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">Neuromuscular blockade</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, and prolonged <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> may occur more commonly in patients with underlying neuromuscular disorders, such as <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or Parkinson's disease. Prolonged <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> may also occur in patients receiving neuromuscular blocking agents. If <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> occurs, it may be reversed by the administration of calcium salts but mechanical assistance may be necessary.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Embryo-Fetal Toxicity
</h2>
<p class="First">Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycosides cross the placenta, and streptomycin has been associated with several reports of total, irreversible, bilateral <span class="product-label-link" type="condition" conceptid="4318712" conceptname="Congenital deafness">congenital deafness</span> in pediatric patients exposed <span class="Italics">in utero</span>. The risk with inhaled tobramycin is less well characterized. Patients who use tobramycin inhalation solution during pregnancy, or become pregnant while taking tobramycin inhalation solution should be apprised of the potential hazard to the fetus.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Concomitant Use of Systemic Aminoglycosides
</h2>
<p class="First">Patients receiving concomitant tobramycin inhalation solution and parenteral aminoglycoside therapy should be monitored as clinically appropriate for toxicities associated with aminoglycosides as a class.  Serum tobramycin levels should be monitored.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s14"></a><a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS
</h1>
<p class="First">The following serious adverse reactions are described below and elsewhere in the labeling:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> <span class="Italics">[see Warnings and Precautions (<a href="#s8">5.1</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> <span class="Italics">[see Warnings and Precautions (<a href="#s9">5.2</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> <span class="Italics">[see Warnings and Precautions (<a href="#s10">5.3</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<p>Tobramycin inhalation solution was studied in two clinical studies in 258 <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients ranging in age from 6 to 48 years. Patients received tobramycin inhalation solution in alternating periods of 28 days on and 28 days off drug in addition to their standard <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> therapy for a total of 24 weeks. Adverse reactions reported in these studies are described below:
</p>
<ul class="Disc">
<li>The most frequent adverse reactions in the tobramycin inhalation arm were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, and increased <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> (see <a href="#t1">Table 1</a>).
</li>
<li>Thirty-three patients (13%) treated with tobramycin inhalation solution complained of <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">voice alteration</span> compared to 17 (7%) placebo patients. <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">Voice alteration</span> was more common in the on-drug periods.
</li>
<li>Eight patients from the tobramycin inhalation solution group (3%) reported <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> compared to no placebo patients. All episodes were transient, resolved without discontinuation of the tobramycin inhalation solution treatment regimen, and were not associated with loss of hearing in audiograms.
</li>
</ul>
<p><a href="#t1">Table 1</a> lists the percent of patients with selected adverse reactions that occurred in &gt;5% of tobramycin inhalation solution patients during the two Phase III studies.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Percent of Patients With Selected Adverse Reactions Occurring in &gt;5% of Tobramycin Inhalation Solution Patients
</span></caption>
<col align="left" width="60.100%">
<col align="left" width="21.267%">
<col align="left" width="18.633%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span> Includes reported decreases in pulmonary function tests or decreased lung volume on chest radiograph associated with intercurrent illness or study drug administration.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Tobramycin Inhalation Solution</span><br><span class="Bold">(n=258)<br>%</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Placebo<br>(n=262)<br>%</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span>
</td>
<td class="Rrule" align="left" valign="top">46.1
</td>
<td class="Rrule" align="left" valign="top">47.3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>
</td>
<td class="Rrule" align="left" valign="top">38.0
</td>
<td class="Rrule" align="left" valign="top">39.3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span> Increased
</td>
<td class="Rrule" align="left" valign="top">37.6
</td>
<td class="Rrule" align="left" valign="top">39.7
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>
</td>
<td class="Rrule" align="left" valign="top">33.7
</td>
<td class="Rrule" align="left" valign="top">38.5
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span>
</td>
<td class="Rrule" align="left" valign="top">19.4
</td>
<td class="Rrule" align="left" valign="top">23.7
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Lung Function Decreased<span class="Sup">1</span>
</td>
<td class="Rrule" align="left" valign="top">16.3
</td>
<td class="Rrule" align="left" valign="top">15.3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">Voice Alteration</span>
</td>
<td class="Rrule" align="left" valign="top">12.8
</td>
<td class="Rrule" align="left" valign="top">6.5
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span>
</td>
<td class="Rrule" align="left" valign="top">6.6
</td>
<td class="Rrule" align="left" valign="top">6.9
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">5.4
</td>
<td class="Botrule Rrule" align="left" valign="top">6.1
</td>
</tr>
</tbody>
</table>
<p>Following are selected adverse reactions that occurred in less than or equal to 5% of patients treated with tobramycin inhalation solution:
</p>
<p><span class="Bold Italics">Ear and labyrinth disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>
</p>
<p><span class="Bold Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>
</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">Laryngitis</span>
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during post approval use of tobramycin inhalation solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</p>
<p><span class="Bold Italics">Ear and labyrinth disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span>:   Some of these reports occurred in patients with previous or concomitant treatment with systemic aminoglycosides. Patients with <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> frequently reported <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. <span class="Italics">[see WARNINGS and Precautions (<a href="#s9">5.2</a>)]</span></p>
<p><span class="Bold Italics">Skin and subcutaneous tissue disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>
</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="40481303" conceptname="Aphonia">Aphonia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>
</p>
<p><span class="Bold Italics">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> <span class="Italics">[see Warnings and Precautions (<a href="#s8">5.1</a>)]</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s17"></a><a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs with Neurotoxic, Nephrotoxic or Ototoxic Potential
</h2>
<p class="First">Concurrent and/or sequential use of tobramycin inhalation solution with other drugs with neurotoxic, nephrotoxic, or ototoxic potential should be avoided if possible.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Diuretics
</h2>
<p class="First">Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. Tobramycin inhalation solution should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s20"></a><a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s21"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Pregnancy Category D
</span><span class="Italics">[See Warnings and Precautions (<a href="#s12">5.5</a>)]</span></p>
<p>Aminoglycosides can cause fetal harm (e.g., <span class="product-label-link" type="condition" conceptid="4318712" conceptname="Congenital deafness">congenital deafness</span>) when administered to a pregnant woman. No adequate and well-controlled studies of tobramycin inhalation solution have been conducted in pregnant women. If tobramycin inhalation solution is used during pregnancy, or if the patient becomes pregnant while taking tobramycin inhalation solution, the patient should be apprised of the potential hazard to the fetus.
</p>
<p>No reproduction toxicology studies have been conducted with tobramycin inhalation solution. However, subcutaneous administration of tobramycin at doses of 100 or 20 mg/kg/day during organogenesis was not teratogenic in rats or rabbits, respectively. Doses of tobramycin ≥40 mg/kg/day were severely maternally toxic to rabbits and precluded the evaluation of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.  <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> was not evaluated in offspring during nonclinical reproduction toxicity studies with tobramycin.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s23"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">It is not known if tobramycin inhalation solution will reach sufficient concentrations after administration by inhalation to be excreted in human breast milk. Because of the potential for <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> in nursing infants from tobramycin inhalation solution, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s24"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">The safety and efficacy of tobramycin inhalation solution have not been studied in pediatric patients under 6 years of age.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s25"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Clinical studies of tobramycin inhalation solution did not include patients aged 65 years and over.  Tobramycin is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function <span class="Italics">[see Warnings and Precautions (<a href="#s10">5.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s26"></a><a name="section-9"></a><p></p>
<h1>10. OVERDOSAGE
</h1>
<p class="First">Signs and symptoms of acute toxicity from overdosage of IV tobramycin might include <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, loss of high-tone hearing acuity, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, and <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>. Administration by inhalation results in low systemic bioavailability of tobramycin. Tobramycin is not significantly absorbed following oral administration. Tobramycin serum concentrations may be helpful in monitoring overdosage.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s27"></a><a name="section-10"></a><p></p>
<h1>11. DESCRIPTION
</h1>
<p class="First">KITABIS PAK contains tobramycin inhalation solution, USP and the PARI LC PLUS Reusable Nebulizer (PARI LC PLUS). Tobramycin inhalation solution is a sterile, clear, slightly yellow, non-pyrogenic, aqueous solution with the pH and salinity adjusted specifically for administration by a compressed air driven PARI LC PLUS Reusable Nebulizer.  The chemical formula for tobramycin is C<span class="Sub">18</span>H<span class="Sub">37</span>N<span class="Sub">5</span>O<span class="Sub">9</span> and the molecular weight is 467.52. Tobramycin is O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→4)-O-[2,6-diamino-2,3,6-trideoxy-α-D-<span class="Italics">ribo</span>-hexopyranosyl-(1→6)]-2-deoxy-L-streptamine. The structural formula for tobramycin is:
</p>
<p><a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-01.jpg"></p>
<p>Each single-use 5 mL ampule contains 300 mg tobramycin and 11.25 mg sodium chloride in sterile water for injection. Sulfuric acid and sodium hydroxide are added to adjust the pH to 6.0. Nitrogen is used for sparging. The formulation contains no preservatives.  The inhalation solution has an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> in the range 135 to 200 mOsmol/kg.
</p>
<p>The PARI LC PLUS Reusable Nebulizer has the following performance characteristics with tobramycin inhalation solution [measured using Next Generation Impactor (NGI) at 15L/min continuous flow, standard conditions (50%RH, 23ºC)]: (1) Delivered Dose: 174 mg; (2) Fine Particle Dose (&lt;5μm): 97 mg; (3) Nebulization Time: 13 min.; (4) <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Median Aerodynamic Diameter: 4.3 μm; (5) Geometric Standard Deviation (GSD): 2.2 μm.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s28"></a><a name="section-11"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s29"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Tobramycin is an antibacterial drug <span class="Italics">[see Clinical Pharmacology (<a href="#s31">12.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s30"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">Tobramycin inhalation solution contains tobramycin, a cationic polar molecule that does not readily cross epithelial membranes. The bioavailability of tobramycin inhalation solution may vary because of individual differences in nebulizer performance and airway pathology. Following administration of tobramycin inhalation solution, tobramycin remains concentrated primarily in the airways.
</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span> Concentrations:</span> Ten minutes after inhalation of the first 300-mg dose of tobramycin inhalation solution, the average concentration of tobramycin was 1237 mcg/g (ranging from 35 to 7414 mcg/g) in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>. Tobramycin does not accumulate in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>; after 20 weeks of therapy with the tobramycin inhalation solution regimen, the average concentration of tobramycin at ten minutes after inhalation was 1154 mcg/g (ranging from 39 to 8085 mcg/g) in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>. High variability of tobramycin concentration in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> was observed. Two hours after inhalation, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> concentrations declined to approximately 14% of tobramycin levels at ten minutes after inhalation.
</p>
<p><span class="Italics">Serum Concentrations:</span> The average serum concentration of tobramycin one hour after inhalation of a single 300 mg dose of tobramycin inhalation solution by <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients was 0.95 mcg/mL. After 20 weeks of therapy on the tobramycin inhalation solution regimen, the average serum tobramycin concentration one hour after dosing was 1.05 mcg/mL.
</p>
<p><span class="Italics">Elimination:</span> The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration. Assuming tobramycin absorbed following inhalation behaves similarly to tobramycin following IV administration, systemically absorbed tobramycin is eliminated principally by glomerular filtration. Unabsorbed tobramycin, following tobramycin inhalation solution administration, is likely eliminated primarily in expectorated <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>.
</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s31"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Mechanism of Action</span></p>
<p>Tobramycin is an aminoglycoside antibacterial produced by <span class="Italics">Streptomyces tenebrarius</span>. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>.
</p>
<p>Tobramycin has in vitro activity against Gram-negative bacteria including <span class="Italics">P. aeruginosa</span>. It is bactericidal in vitro at peak concentrations equal to or slightly greater than the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics">Susceptibility Testing</span></p>
<p>Interpretive criteria for inhaled antibacterial products are not defined. In vitro antimicrobial susceptibility test methods used to determine the susceptibility for parenteral tobramycin therapy can be used to monitor the susceptibility of <span class="Italics">P. aeruginosa</span> isolated from <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients.<span class="Sup">(1,2,3)</span>  The relationship between in vitro susceptibility test results and clinical outcome with tobramycin inhalation solution therapy is not clear. A single <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> sample from a <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patient may contain multiple morphotypes of <span class="Italics">P. aeruginosa</span> and each morphotype may require a different concentration of tobramycin to inhibit its growth in vitro.  Patients should be monitored for changes in tobramycin susceptibility.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s34"></a><a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s35"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">A two-year rat inhalation toxicology study to assess carcinogenic potential of tobramycin inhalation solution has been completed. Rats were exposed to tobramycin inhalation solution for up to 1.5 hours per day for 95 weeks. The clinical formulation of the drug was used for this carcinogenicity study. Serum levels of tobramycin of up to 35 mcg/mL were measured in rats, in contrast to the average 1 mcg/mL levels observed in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients in clinical trials. There was no drug-related increase in the incidence of any variety of tumor.
</p>
<p>Additionally, tobramycin has been evaluated for genotoxicity in a battery of in vitro and in vivo tests. The Ames bacterial reversion test, conducted with 5 tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, failed to show a significant increase in revertants with or without metabolic activation in all <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. Tobramycin was negative in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay, did not induce chromosomal aberrations in Chinese hamster ovary cells, and was negative in the mouse micronucleus test.
</p>
<p>Subcutaneous administration of up to 100 mg/kg of tobramycin did not affect mating behavior or cause impairment of fertility in male or female rats.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s36"></a><a name="section-13"></a><p></p>
<h1>14. CLINICAL STUDIES
</h1>
<p class="First">Two identically designed, double-blind, randomized, placebo-controlled, parallel group, 24-week clinical studies (Study 1 and Study 2) at a total of 69 <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> centers in the United States were conducted in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients with <span class="Italics">P. aeruginosa</span> with tobramycin inhalation solution. Subjects who were less than 6 years of age, had a baseline creatinine of &gt;2 mg/dL, or had <span class="Italics">Burkholderia cepacia</span> isolated from <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> were excluded. All subjects had baseline FEV<span class="Sub">1</span> % predicted between 25% and 75%. In these clinical studies, 258 patients received tobramycin inhalation solution therapy on an outpatient basis (see <a href="#t2">Table 2</a>) using a PARI LC PLUS nebulizer along with a DeVilbiss Pulmo-Aide compressor.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Dosing Regimens in Clinical Studies
</span></caption>
<col align="left" width="18.003%">
<col align="left" width="13.445%">
<col align="left" width="13.459%">
<col align="left" width="13.773%">
<col align="left" width="13.773%">
<col align="left" width="13.773%">
<col align="left" width="13.773%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Cycle 1</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Cycle 2</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Cycle 3</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top">28 days
</td>
<td class="Botrule Rrule" align="left" valign="top">28 days
</td>
<td class="Botrule" align="left" valign="top">28 days
</td>
<td class="Botrule Rrule" align="left" valign="top">28 days
</td>
<td class="Botrule" align="left" valign="top">28 days
</td>
<td class="Botrule Rrule" align="left" valign="top">28 days
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">TOBRAMYCIN<br>Inhalation<br>Solution<br>regimen<br>n=258
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">TOBRAMYCIN   No drug<br>Inhalation<br>Solution<br>300 mg<br>BID
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">TOBRAMYCIN   No drug<br>Inhalation<br>Solution<br>300 mg<br>BID
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">TOBRAMYCIN   No drug<br>Inhalation<br>Solution<br>300 mg<br>BID
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo<br>regimen<br>n=262
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">Placebo<br>BID
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">Placebo<br>BID
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">Placebo<br>BID
</td>
</tr>
</tbody>
</table>
<p>All patients received either tobramycin inhalation solution or placebo (saline with 1.25 mg quinine for flavoring) in addition to standard treatment recommended for <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients, which included oral and parenteral anti-pseudomonal therapy, Beta 2-agonists, cromolyn, inhaled steroids, and airway clearance techniques. In addition, approximately 77% of patients were concurrently treated with dornase alfa.
</p>
<p>In each study, tobramycin inhalation solution -treated patients experienced significant improvement in pulmonary function. Improvement was demonstrated in the tobramycin inhalation solution group in Study 1 by an average increase in FEV<span class="Sub">1</span> % predicted of about 11% relative to baseline (Week 0) during 24 weeks compared to no average change in placebo patients. In Study 2, tobramycin inhalation solution -treated patients had an average increase of about 7% compared to an average decrease of about 1% in placebo patients. <a href="#fig1">Figure 1</a> shows the average relative change in FEV<span class="Sub">1</span> % predicted over 24 weeks for both studies.
</p>
<p><a name="fig1"></a><span class="Bold">Figure 1: Relative Change From Baseline in FEV</span><span class="Bold"><span class="Sub">1</span></span><span class="Bold">% Predicted</span></p>
<p><a name="f02"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-02.jpg"></p>
<p>In each study, tobramycin inhalation solution therapy resulted in a significant reduction in the number of <span class="Italics">P. aeruginosa</span> colony forming units (CFUs) in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> during the on-drug periods. <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span> bacterial density returned to baseline during the off-drug periods. Reductions in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> bacterial density were smaller in each successive cycle. (see <a href="#fig2">Figure 2</a>).
</p>
<p><a name="fig2"></a><span class="Bold">Figure 2: Absolute Change From Baseline in Log</span><span class="Bold"><span class="Sub">10
</span></span><span class="Bold">CFUs</span></p>
<p><a name="f03"></a><img alt="Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-03.jpg"></p>
<p>Patients treated with tobramycin inhalation solution were hospitalized for an average of 5.1 days compared to 8.1 days for placebo patients. Patients treated with tobramycin inhalation solution required an average of 9.6 days of parenteral anti-pseudomonal antibiotic treatment compared to 14.1 days for placebo patients. During the 6 months of treatment, 40% of tobramycin inhalation solution patients and 53% of placebo patients were treated with parenteral anti-pseudomonal antibiotics.
</p>
<p>The relationship between in-vitro susceptibility test results and clinical outcome with tobramycin inhalation solution therapy is not clear. However, 4 tobramycin inhalation solution patients who began the clinical trial with P. <span class="Italics">aeruginosa</span> isolates having MIC values ≥128 μg/mL did not experience an improvement in FEV<span class="Sub">1</span> or a decrease in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> bacterial density.
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s37"></a><a name="section-14"></a><p></p>
<h1>15. REFERENCES
</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition</span>. CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Eleventh Edition.</span> CLSI document M02-A11, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fourth Informational Supplement</span>, CLSI document M100-S24, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2014.
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s38"></a><a name="section-15"></a><p></p>
<h1>16. HOW SUPPLIED / STORAGE AND HANDLING
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied
</h2>
<p class="First">KITABIS PAK co-packaged kit (NDC 24492-850-56) is available in cartons containing one reusable PARI LC Plus nebulizer (Model No.: 022B81-T) and 14 tobramycin inhalation solution pouches. Each pouch contains four 300mg/5mL ampules of tobramycin inhalation solution for a total of 56 ampules in each carton. Each carton constitutes a 28 day supply.
</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s40"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage
</h2>
<ul class="Disc">
<li>Tobramycin inhalation solution should be stored under refrigeration at 2-8ºC/36-46ºF. Upon removal from the refrigerator, or if refrigeration is unavailable, tobramycin inhalation solution pouches (opened or unopened) may be stored at room temperature (up to 25<span class="Sup">º</span>C/77ºF) for up to 28 days. Tobramycin inhalation solution should not be used beyond the expiration date stamped on the ampule when stored under refrigeration (2-8ºC/36-46ºF) or beyond 28 days when stored at room temperature (25ºC/77ºF).
</li>
<li>Tobramycin inhalation solution ampules should not be exposed to intense light. The solution in the ampule is slightly yellow, but may darken with age if not stored in the refrigerator; however, the color change does not indicate any change in the quality of the product as long as it is stored within the recommended storage conditions.
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s41"></a><a name="section-16"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (<a href="#s48">Patient Information</a> and <a href="#s49">Instructions for Use</a>). 
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-16.1"></a><p></p>
<p class="First"><span class="Underline">Instructions for Administration</span></p>
<p>Instruct patients to read the <span class="Italics">Instructions for Use</span> before starting KITABIS PAK. Instruct patients to use the tobramycin inhalation solution in KITABIS PAK only with the PARI LC PLUS Reusable Nebulizer included in the KITABIS PAK.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-16.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Difficulty Breathing</span></span></p>
<p>Advise patients to inform their physicians if they experience <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> soon after administration of tobramycin inhalation solution.  Tobramycin inhalation solution can cause a narrowing of the airway <span class="Italics">[see Warnings and Precautions (<a href="#s8">5.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-16.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing Loss</span></span></p>
<p>Advise patients to inform their physician if they experience ringing in the ears, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or any changes in hearing because tobramycin inhalation solution is in a class of drugs that have caused <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> <span class="Italics">[see Warnings and Precautions (<a href="#s9">5.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-16.4"></a><p></p>
<p class="First"><span class="Underline">Kidney Damage</span></p>
<p>Advise patients to inform their physician if they have any history of kidney problems because tobramycin inhalation solution is in a class of drugs that have caused kidney damage <span class="Italics">[see Warnings and Precautions (<a href="#s10">5.3</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-16.5"></a><p></p>
<p class="First"><span class="Underline">Pregnancy</span></p>
<p>Advise patients to talk with their physician if they want to become pregnant while on tobramycin inhalation solution because tobramycin inhalation solution is in a class of antibacterial drugs that have caused harm to the fetus <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.5</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-16.6"></a><p></p>
<p class="First"><span class="Underline">Nursing Mothers</span></p>
<p>Advise patients to talk with their physician before using tobramycin inhalation solution while nursing a baby <span class="Italics">[see Use in Specific Populations (<a href="#s23">8.3</a>)]</span>.</p>
<p><span class="Bold">Additional Information</span>PARI LC PLUS<span class="Sup">®</span> Reusable Nebulizer: 1-800-327-8632<br>Devilbiss<span class="Sup">®</span> Pulmo-Aide<span class="Sup">®</span> air compressor: 1-800-338-1988<br>KITABIS PAK: 1-844-KITABIS (548-2247)</p>
<p><span class="Bold">Manufactured by:<br>Catalent Pharma Solutions, LLC<br>Woodstock, IL 60098</span></p>
<p><span class="Bold">Distributed by:</span></p>
<p><img alt="PARI Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-04.jpg"></p>
<p>PARI Respiratory Equipment, Inc.<br>2412 PARI Way, Midlothian, VA 23112</p>
<p>850D5601 Rev B 11/2014</p>
<p>© 2013-2014 PulmoFlow, Inc.. All rights reserved.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s48"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Patient Information <br>KITABIS™ PAK (Ki  TAH  biss  Pak) <br>(tobramycin inhalation solution)<br>for oral inhalation</span></p>
<p>Read this Patient Information before you start using KITABIS PAK and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.
</p>
<p><span class="Bold">What is KITABIS PAK?</span></p>
<p>KITABIS PAK contains a prescription medicine and a PARI LC PLUS Reusable Nebulizer used to treat adults and children 6 years of age and older with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> who have a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> called Pseudomonas aeruginosa. KITABIS PAK contains an antibacterial medicine called tobramycin (an aminoglycoside).
</p>
<p>It is not known if KITABIS PAK is safe and effective:
</p>
<ul class="Disc">
<li>in children under 6 years of age
</li>
<li>in people who have decreased lung volume or an FEV<span class="Sub">1</span> less than 25% or greater than 75% predicted
</li>
<li>in people who are colonized with a bacterium called Burkholderia cepacia
</li>
<li>when used for more than 3 cycles  
</li>
</ul>
<p><span class="Bold">Who should not use KITABIS PAK?</span>  
                  </p>
<p>Do not use KITABIS PAK if you are allergic to tobramycin, any of the ingredients in KITABIS PAK, or to any other aminoglycoside antibacterial medicine.  
</p>
<p><span class="Bold">What should I tell my healthcare provider before using KITABIS PAK?</span></p>
<p><span class="Bold">Before you use KITABIS PAK, tell your healthcare provider if you:</span></p>
<ul class="Disc">
<li>have or have had hearing problems (including noises in your ears)
</li>
<li>have <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>
</li>
<li>have or have had kidney problems
</li>
<li>have or have had problems with <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> such as <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or Parkinson's disease
</li>
<li>have or have had breathing problems such as <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, or <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>
</li>
<li>have had an organ transplant
</li>
<li>are pregnant or plan to become pregnant. See “<a href="#p01">What are the possible side effects of KITABIS PAK?</a>? below for more information.
</li>
<li>are breastfeeding or plan to breastfeed. It is not known if the medicine in KITABIS PAK (tobramycin inhalation solution) passes into your breast milk.
</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and over-the-counter, vitamins, and herbal supplements.
</p>
<p>Using KITABIS PAK with certain other medicines can cause serious side effects.
</p>
<p>If you are using KITABIS PAK, you should discuss with your healthcare provider if you should take:
</p>
<ul class="Disc">
<li>other medicines that may harm your nervous system, kidneys, or hearing
</li>
<li>“water pills? (diuretics) such as Edecrin (ethacrynic acid), Lasix (furosemide),  or mannitol
</li>
<li>urea  
</li>
</ul>
<p> Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.  
</p>
<p>Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.  
</p>
<p><span class="Bold">How should I use KITABIS PAK?</span></p>
<ul class="Disc">
<li>See the step-by-step Instructions for Use at the end of this Patient Information leaflet about the right way to use KITABIS PAK.
</li>
<li>Use KITABIS PAK exactly as your healthcare provider tells you to. Ask your healthcare provider or pharmacist if you are not sure.
</li>
<li>The usual dose of KITABIS PAK for adults and children 6 years of age and over is:<ul class="Circle"><li>1 ampule of tobramycin inhalation solution inhaled by mouth in the morning and 1 ampule of tobramycin inhalation solution inhaled by mouth in the evening using your PARI LC PLUS Reusable Nebulizer with a DeVilbiss Pulmo-Aide air compressor.
</li></ul>
</li>
<li>Each dose of KITABIS PAK should take about 15 minutes to finish.
</li>
<li>Each dose of KITABIS PAK should be used as close to 12 hours apart as possible.
</li>
<li>Do not use your dose of KITABIS PAK less than 6 hours apart.
</li>
<li>After using KITABIS PAK for 28 days, you should stop using it for 28 days. After you have stopped using KITABIS PAK for 28 days, you should start using KITABIS PAK again for 28 days. It is important that you keep to the 28-day on, 28-day off cycle.
</li>
<li>Do not mix the medicine in KITABIS PAK with other medicines including dornase alfa (Pulmozyme®) in your nebulizer.
</li>
<li>If you are taking other medicines inhaled through your mouth (bronchodilators), your healthcare provider will tell you how to take your medicine the right way.
</li>
<li>If you inhale too much of the medicine in KITABIS PAK, tell your healthcare provider right away.  
</li>
</ul>
<p><a name="p01"></a><span class="Bold">What are the possible side effects of KITABIS PAK?</span></p>
<p><span class="Bold">KITABIS PAK can cause serious side effects, including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">severe breathing problems (<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>).</span> Tell your healthcare provider right away if you get any of these symptoms of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> while using KITABIS PAK:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> with <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> and <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>
</li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> or ringing in the ears (<span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>).</span> Tell your healthcare provider right away if you have <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> or hear noises in your ears (such as ringing or hissing), or if you develop <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or difficulty with balance.
</li>
<li>
<span class="Bold">worsening kidney problems (<span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>).</span> Your healthcare provider may do a blood test and urine test to check how your kidneys are working while you are using KITABIS PAK.
</li>
<li>
<span class="Bold">worsening <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.</span> The medicine in KITABIS PAK (tobramycin inhalation solution) is in a class of medicines that can cause <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> to get worse in people who already have problems with <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> (<span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or Parkinson's disease).
</li>
<li><span class="Bold">The medicine in KITABIS PAK (tobramycin inhalation solution) is in a class of medicines which may cause harm to an unborn baby.</span></li>
</ul>
<p><span class="Bold">The most common side effects of KITABIS PAK include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">productive cough</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood
</li>
<li>worsening of lung problems or <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>
</li>
<li>changes in your voice (<span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>)
</li>
<li>altered taste
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>  
</li>
</ul>
<p> Tell your healthcare provider about any side effect that bothers you or that does not go away.  
</p>
<p>These are not all of the possible side effects of KITABIS PAK. For more information, ask your healthcare provider or pharmacist.
</p>
<p> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.  
</p>
<p><span class="Bold">General information about the safe and effective use of KITABIS PAK.</span>  
                  </p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use KITABIS PAK for a condition for which it was not prescribed. Do not give KITABIS PAK to other people, even if they have the same symptoms that you have. It may harm them.  
</p>
<p>This leaflet summarizes the most important information about KITABIS PAK. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about KITABIS PAK that is written for health professionals.  
</p>
<p>For more information, go to <span class="Underline">www.KITABIS.com</span> or call 1-844-KITABIS(548-2247).
</p>
<p><span class="Bold">What are the ingredients in KITABIS PAK?</span></p>
<p><span class="Bold">Active ingredient:</span> tobramycin
</p>
<p><span class="Bold">Inactive ingredients:</span> sodium chloride, sulfuric acid, and sodium hydroxide (for pH adjustment)
</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="s49"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Instructions for Use<br>KITABIS PAK (Ki TAH biss Pak)<br>(tobramycin inhalation solution)</span></p>
<p>Follow the instructions below for using KITABIS PAK which contains tobramycin inhalation solution and the PARI LC PLUS Reusable Nebulizer (PARI LC PLUS). If you have any questions, ask your healthcare provider or pharmacist.</p>
<p>Each KITABIS PAK carton (28-day supply) contains 56 tobramycin inhalation solution ampules packed in 14 foil pouches that each contain 4 single-use tobramycin inhalation solution ampules.</p>
<p><span class="Bold">You will need the following supplies (See <a href="#f05">Figure A</a>):</span></p>
<ul class="Disc">
<li>1 tobramycin inhalation solution ampule</li>
<li>PARI LC PLUS<span class="Sup">®</span> Reusable Nebulizer</li>
<li>DeVilbiss Pulmo-Aide (Pulmo-Aide) air compressor</li>
<li>tubing to connect the nebulizer and compressor</li>
<li>clean, lint-free towel</li>
<li>nose clip (optional, not pictured)</li>
</ul>
<div class="Figure"><img alt="Figure A
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-05.jpg"></div>
<p class="MultiMediaCaption">(Figure A)</p>
<p class="MultiMediaCaption"></p>
<p><span class="Bold">Note: Read the Instructions for Use that come with your PARI LC PLUS Reusable Nebulizer and DeVilbiss Pulmo-Aide air compressor for detailed instructions on how to use and care for your nebulizer and air compressor before you use it.</span></p>
<p><span class="Bold">Do not</span> mix the medicine in KITABIS PAK with other medicines in your nebulizer.</p>
<p>The medicine in KITABIS PAK (tobramycin inhalation solution) comes in a sealed foil pouch. Do not open a sealed pouch until you are ready to use a dose. After opening the pouch, unopened ampules should be returned to and stored in the pouch.</p>
<p><span class="Bold">Getting ready:</span></p>
<p>Open the PARI LC PLUS package. Place the PARI LC PLUS parts including Top and Bottom (Nebulizer Cup) Assembly, Inspiratory Valve Cap, Mouthpiece with Valve, and Tubing on a clean, dry surface or towel (See <a href="#f06">Figure B</a>).</p>
<div class="Figure"><img alt="Figure B
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-06.jpg"></div>
<p class="MultiMediaCaption">(Figure B)</p>
<p class="MultiMediaCaption"></p>
<p><span class="Bold">Preparing your KITABIS PAK dose:</span></p>
<p><span class="Bold">Step 1:</span> Wash your hands with soap and water (See <a href="#f07">Figure C</a>).</p>
<div class="Figure"><img alt="Figure C
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-07.jpg"></div>
<p class="MultiMediaCaption">(Figure C)</p>
<p class="MultiMediaCaption"></p>
<p><span class="Bold">Step 2:</span> Open the foil pouch (See <a href="#f08">Figure D</a>).</p>
<p><img alt="Figure D
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-08.jpg"></p>
<p><span class="Bold">Step 3:</span> Separate 1 ampule by gently pulling apart at the TOP of the ampule and continue down to the bottom tabs (See <a href="#f09">Figure E</a>) and use it right away.</p>
<p><img alt="Figure E
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-09.jpg"></p>
<p><span class="Bold">Step 4:</span> Hold the bottom tab on the KITABIS PAK ampule with 1 hand (See <a href="#f10">Figure F</a>). With your other hand, hold the top of the ampule and twist off the top of the ampule (See <a href="#f10">Figure F</a>).</p>
<ul class="Disc"><li>
<span class="Bold">Do not</span> squeeze the ampule until you are ready to squeeze all of the medicine into the Nebulizer Cup.</li></ul>
<p><img alt="Figure F
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-10.jpg"></p>
<p><span class="Bold">Step 5:</span> Hold the Nebulizer Cup and twist off the Nebulizer Insert or Top in a counter-clockwise direction (See <a href="#f11">Figure G</a>). Set the top aside on a clean, dry, surface.</p>
<p><img alt="Figure G
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-11.jpg"></p>
<p><span class="Bold">Step 6:</span> Squeeze all the medicine from the ampule into the Nebulizer Cup (See <a href="#f12">Figure H</a>).</p>
<p><img alt="Figure H
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-12.jpg"></p>
<p><span class="Bold">Step 7:</span> Replace the Nebulizer Cup Insert. Line up the semi-circle on the Nebulizer Insert with the Nebulizer Outlet and twist on the Nebulizer Cup Insert in a clock-wise direction until it is tight and the alignment rings are lined up (See <a href="#f13">Figure I</a>).</p>
<p><img alt="Figure I
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-13.jpg"></p>
<p><span class="Bold">Step 8:</span> Push the Mouthpiece straight onto the Nebulizer Cup (See <a href="#f14">Figure J</a>).</p>
<p><img alt="Figure J
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-14.jpg"></p>
<p><span class="Bold">Step 9:</span> Firmly push the Inspiratory Valve Cap straight down onto the Nebulizer Cup Top (See <a href="#f15">Figure K</a>). The Inspiratory Valve Cap should fit tightly.</p>
<p><img alt="Figure K
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-15.jpg"></p>
<p><span class="Bold">Step 10:</span> Connect 1 end of the tubing to the compressor air outlet (See <a href="#f16">Figure L</a>). The tubing should fit tightly.</p>
<p><img alt="Figure L
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-16.jpg"></p>
<p><span class="Bold">Step 11:</span> Plug your compressor into an electrical outlet (See <a href="#f17">Figure M</a>).</p>
<p><img alt="Figure M
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-17.jpg"></p>
<p><span class="Bold">Step 12:</span> Hold the Nebulizer Cup upright and firmly push the free end of the tubing straight up onto the Air Intake on the bottom of the Nebulizer Cup (See <a href="#f18">Figure N</a>). <span class="Bold">Make sure to keep the Nebulizer Cup upright.</span></p>
<p><img alt="Figure N
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-18.jpg"></p>
<p><span class="Bold">Giving your KITABIS PAK dose:</span></p>
<p><span class="Bold">Step 13:</span> Turn on the compressor (See <a href="#f19">Figure O</a>). You should see a steady mist coming from the Mouthpiece (See <a href="#f20">Figure P</a>).</p>
<p><img alt="Figure O
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-19.jpg"></p>
<p><img alt="Figure P
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-20.jpg"></p>
<p><span class="Bold">Step 14:</span> Sit or stand in a comfortable, upright position that will allow you to breathe normally. Place the Mouthpiece between your teeth and on top of your tongue and breathe normally only through your mouth (See <a href="#f21">Figure Q</a>).</p>
<ul class="Disc"><li>Nose clips may help you breathe only through your mouth and not through your nose.</li></ul>
<p><img alt="Figure Q
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-21.jpg"></p>
<p><span class="Bold">Step 15:</span> Keep breathing in your KITABIS PAK dose for at least 15 minutes. You will know that you have received your full dose of medicine when you hear a “sputtering noise? coming from the Mouthpiece for at least 1 minute and the Nebulizer Cup is empty.</p>
<p><span class="Bold">After your KITABIS PAK dose:</span></p>
<p><span class="Bold">Step 16:</span> Clean and disinfect your nebulizer (see manufacturer's Instructions for Use).</p>
<p><span class="Bold">Care and Use of your DeVilbiss Pulmo-Aide compressor:</span></p>
<p>Follow the manufacturer's instructions for care and use of your compressor.</p>
<p><span class="Bold">How should I store KITABIS PAK?</span></p>
<ul class="Disc">
<li>Store tobramycin inhalation solution in the refrigerator between 36°F to 46°F (2°C to 8°C) until needed.</li>
<li>You may store the tobramycin inhalation solution in the foil pouches (opened or unopened) at room temperature between 66°F to 77°F (20°C to 25°C) for up to 28 days.</li>
<li>Do not use tobramycin inhalation solution after the expiration date stamped on the ampule.</li>
<li>Keep tobramycin inhalation solution in the foil pouch and out of the light.</li>
<li>Tobramycin inhalation solution is normally slightly yellow, but may get darker with age if unrefrigerated. The color change does not change how the medicine works.</li>
<li>
<span class="Bold">Do not</span> use tobramycin inhalation solution if it is cloudy, has particles in the solution, or if it has been stored at room temperature for more than 28 days. Throw the applicable ampule(s) away in the household trash and get a new ampule.</li>
</ul>
<p>Keep KITABIS PAK and all medicines out of the reach of children.</p>
<p>This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Additional Information</span>PARI LC PLUS<span class="Sup">®</span> Reusable Nebulizer: 1-800-327-8632<br>Devilbiss<span class="Sup">®</span> Pulmo-Aide<span class="Sup">®</span> air compressor: 1-800-338-1988<br>KITABIS PAK: 1-844-KITABIS (548-2247)</p>
<p><span class="Bold">Manufactured by:<br>Catalent Pharma Solutions, LLC<br>Woodstock, IL 60098</span></p>
<p><span class="Bold">Distributed by:</span></p>
<p><img alt="PARI Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-22.jpg"></p>
<p>PARI Respiratory Equipment, Inc.<br>2412 PARI Way, Midlothian, VA 23112</p>
<p>850D5601 Rev B 11/2014<br>© 2013-2014 PulmoFlow, Inc.. All rights reserved.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Lfb36c1e0-56a4-4a79-961c-a8f5734efeb2"></a><a name="section-19"></a><p></p>
<h1>Principal Display Panel - Kitabis Pak</h1>
<p class="First"></p>
<p>NDC:  24492-850-56</p>
<p>PARI</p>
<p>Kitabis<span class="Sup">TM</span> Pak</p>
<p>Tobramycin Inhalation Solution, USP</p>
<p>Store in Refrigerator</p>
<p>Includes One PARI LC PLUS Nebulizer Set</p>
<p>Rx only</p>
<p><img alt="carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f&amp;name=kit00-0000-23.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KITABIS PAK 		
					</strong><br><span class="contentTableReg">tobramycin solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24492-850</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Tobramycin</strong> (Tobramycin) </td>
<td class="formItem">Tobramycin</td>
<td class="formItem">300 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sulfuric Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24492-850-56</td>
<td class="formItem">14  in 1 CARTON</td>
<td class="formItem">12/02/2014</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 AMPULE; Combination Product Type = C102837</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205433</td>
<td class="formItem">12/02/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pari Respiratory Equipment
							(804736098)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fc9174e2-7de8-4c29-abda-0e723438eb28</div>
<div>Set id: da1e5afd-d707-4af1-8935-8195ba6d769f</div>
<div>Version: 3</div>
<div>Effective Time: 20141220</div>
</div>
</div> <div class="DistributorName">Pari Respiratory Equipment</div></p>
</body></html>
